CD276 and breast carcinoma: Additionally, in the realm of CAR-T and CAR-NK therapy for breast cancer, several targets, such as EpCAM (NCT02915445), VEGFR (NCT05477927), EGFR, and B7-H3 (NCT05341492), have been explored in clinical trials.